Vectura is a specialist inhalation CDMO providing innovative inhaled drug delivery solutions. With differentiated proprietary technology and pharmaceutical development expertise, Vectura applies extensive device, formulation and development capabilities.
Associated CompaniesSkyepharma Production
Vectura is a specialist inhalation CDMO that provides innovative inhaled drug delivery solutions that enable customers to bring their medicines to patients. With differentiated proprietary technology and pharmaceutical development expertise, Vectura is one of the few companies globally with the device, formulation and development capabilities to deliver a broad range of complex inhaled therapies. Vectura has 13 key inhaled and 11 non-inhaled products marketed by partners with global royalty streams, and a diverse partnered portfolio of drugs in clinical development.
The company was founded in 1997, with its origins in the University of Bath (UK). The company has made several significant acquisitions in the respiratory space, including Innovata plc in 2007 and Activaero in 2014, and in 2016 it merged with Skyepharma, retaining the name Vectura. Its shares were publicly traded from 2004, most recently on the London Stock Exchange (LSE:VEC), until it was acquired by Philip Morris International in September 2021.